Barington Takes $5.56M Position in Chemed as Stock Slides 15% YoY

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

Barington Companies buys $5.56M stake in Chemed as stock drops 15% YoY, viewing depressed valuation as opportunity in healthcare-services company.

Barington Takes $5.56M Position in Chemed as Stock Slides 15% YoY

Barington Companies Management has initiated a new position in Chemed Corporation, purchasing 13,000 shares valued at $5.56 million, which represents 3.65% of the investment firm's reportable assets. The stake establishment comes as Chemed's stock has declined 15.18% over the past twelve months, suggesting the institutional investor views current valuation levels as an opportunity to gain exposure to the diversified healthcare and services company.

Chemed operates two primary business divisions: VITAS, a leading provider of hospice and palliative care services, and Roto-Rooter, which offers residential and commercial plumbing services. The company has maintained a strong balance sheet and consistent cash generation capabilities, though recent margin pressures have weighed on operational performance and contributed to the stock's underperformance relative to broader market indices.

Barington's investment reflects a contrarian positioning in a company whose defensive business characteristics—particularly in essential services like hospice care and emergency plumbing—typically insulate it from broader economic cycles. The firm's decision to establish a material position suggests management believes the current market discount adequately compensates for near-term operational headwinds.

Source: The Motley Fool

Back to newsPublished Feb 16

Related Coverage

GlobeNewswire Inc.

POET Technologies Hit with Securities Fraud Lawsuit Over PFIC Disclosure Failures

Kirby McInerney LLP files class action against POET Technologies for alleged securities fraud involving PFIC misrepresentation and confidentiality breaches, triggering steep stock declines.

POET
GlobeNewswire Inc.

ImmunityBio Stock Plummets 21% After FDA Warning Over Anktiva Cancer Claims

ImmunityBio faces securities fraud lawsuit after FDA warning letter alleges false Anktiva promotional claims. Stock dropped 21% to $7.42.

IBRX
Benzinga

Johnson Outdoors Beats Earnings But Cost Pressures Weigh on Stock

Johnson Outdoors delivered strong Q2 results with 16% sales growth and margin expansion, but flagged mounting cost pressures and inventory challenges, causing shares to decline.

JOUT
The Motley Fool

MercadoLibre Stock Plunges 11% Despite Revenue Beat and Strong Cash Flow

MercadoLibre shares fell 11% after Q1 earnings beat revenue expectations but missed profit forecasts, as the company invests heavily in growth. Free cash flow doubled to $1.8B, trading at attractive 7.1x FCF multiple.

MELI
Benzinga

BT Brands Stock Crashes 35% After Merger Deal Collapses Over SEC Filing Delay

$BTBD plummets 35% after-hours following termination of Aero Velocity merger. SEC registration statement failed to become effective by April 30 deadline.

BTBDBTBDW
GlobeNewswire Inc.

Sportradar Stock Plunges 22.6% on Illegal Gambling Allegations, Class Action Looms

Sportradar stock crashed 22.6% after Muddy Waters alleged illegal gambling connections. Rosen Law Firm investigating for class action lawsuit.

SRAD